LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Trial details
- Registry ID
- NCT05983250
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250 | TENX | Phase 3 | Active not recruiting | 2026-06-30Actual |
| Long-Term Open-Label Extension Study of Oral LevosimendanNCT07436689 | TENX | Phase 3 | Enrolling by invitation | 2029-03Estimated |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT07288398 | TENX | Phase 3 | Active not recruiting | 2028-06-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |